The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:1687-1688 April 19, 2007 Number 16
NextNext

Recombinant PTH for Initial Management of Neonatal Hypocalcemia

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: Neonatal hypocalcemia due to hypoparathyroidism can present as life-threatening seizures or tetany. Currently, initial management consists of the administration of calcitriol and high doses of calcium. In symptomatic children, to avoid extravasation, intravenous calcium is best administered through a central line, a procedure that requires proper expertise. However, central access carries the risks of infection and thrombosis. Correction of hypocalcemia with intravenous and oral calcium often takes a day or longer to achieve, leaving the infant at risk for seizures and tetany. Therefore, recombinant parathyroid hormone (teriparatide) should be a faster, safer, and more physiologic means of . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.